Stay updated on Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.

Latest updates to the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA sitewide NIH announcement about the terminology transition from “Artificial Intelligence” to “Super Intelligence” was removed. The study page continues to show a 403 Forbidden error.SummaryDifference1%

- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the ClinicalTrials.gov error page.SummaryDifference1%

- Check29 days agoChange DetectedThe displayed site revision changes from v3.7.1 to v3.7.2, while the page remains a 403 Forbidden error screen.SummaryDifference0.3%

- Check36 days agoChange DetectedThe ClinicalTrials.gov footer revision label updates from v3.7.0 to v3.7.1; the page continues to show a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record page for NCT02383927 now displays a 403 Forbidden error page instead of the usual study details, replacing content with a generic error screen. This indicates an access restriction or server-side issue preventing viewing the study record on ClinicalTrials.gov.SummaryDifference18%

Stay in the know with updates to Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.